Enzon Pharmaceuticals Inc (ENZN) financial statements (2021 and earlier)
Company profile
| Business Address |
20 COMMERCE DRIVE, SUITE 135 CRANFORD, NJ 07016 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 48 | 5 | 7 | 7 | 8 | 12 | 35 | ||
| Cash and cash equivalents | 48 | 5 | 7 | 7 | 8 | 12 | 35 | ||
| Receivables | 0 | 1 | 4 | ||||||
| Deferred tax assets | ✕ | ✕ | 77 | ||||||
| Other current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Other undisclosed current assets | 0 | 7 | (4) | ||||||
| Total current assets: | 48 | 6 | 15 | 8 | 8 | 12 | 112 | ||
| Noncurrent Assets | |||||||||
| Nontrade receivables | 0 | 1 | 2 | ||||||
| Deferred tax assets, net | ✕ | ✕ | 3 | 11 | |||||
| Total noncurrent assets: | 0 | 1 | 2 | 3 | 11 | ||||
| Other undisclosed assets | (77) | ||||||||
| TOTAL ASSETS: | 48 | 6 | 16 | 10 | 11 | 23 | 35 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 0 | 0 | 1 | 0 | 1 | 0 | 5 | ||
| Accounts payable | 0 | 0 | 0 | 0 | 1 | 0 | 0 | ||
| Accrued liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Employee-related liabilities | 0 | ||||||||
| Interest and dividends payable | 4 | ||||||||
| Other undisclosed current liabilities | 5 | (0) | |||||||
| Total current liabilities: | 0 | 0 | 1 | 0 | 1 | 5 | 5 | ||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 0 | ||||||||
| Accounts payable and accrued liabilities | 0 | ||||||||
| Total noncurrent liabilities: | 0 | ||||||||
| Total liabilities: | 0 | 0 | 1 | 0 | 1 | 5 | 5 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 7 | 6 | 15 | 9 | 10 | 18 | 30 | ||
| Common stock | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Additional paid in capital | 78 | 76 | 84 | 84 | 90 | 97 | 130 | ||
| Accumulated deficit | (71) | (70) | (69) | (75) | (80) | (79) | (101) | ||
| Total stockholders' equity: | 7 | 6 | 15 | 9 | 10 | 18 | 30 | ||
| Other undisclosed liabilities and equity | 40 | ||||||||
| TOTAL LIABILITIES AND EQUITY: | 48 | 6 | 16 | 10 | 11 | 23 | 35 | ||
Income statement (P&L) ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue, net | ✕ | ✕ | ✕ | 8 | 8 | 17 | 31 | |
| Gross profit: | 0 | 0 | 7 | 8 | 8 | 17 | 31 | |
| Operating expenses | (1) | (1) | (1) | (1) | (2) | (7) | (2) | |
| Operating income (loss): | (1) | (1) | 6 | 7 | 7 | 11 | 29 | |
| Nonoperating income (Other Nonoperating income) | 0 | 0 | ||||||
| Income (loss) from continuing operations before income taxes: | (1) | (1) | 6 | 7 | 7 | 11 | 29 | |
| Income tax expense (benefit) | (0) | (0) | (0) | (2) | (8) | 11 | (0) | |
| Net income (loss) attributable to parent: | (1) | (1) | 6 | 5 | (1) | 22 | 29 | |
| Preferred stock dividends and other adjustments | (0) | |||||||
| Net income (loss) available to common stockholders, diluted: | (2) | (1) | 6 | 5 | (1) | 22 | 29 | |
Comprehensive Income ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (1) | (1) | 6 | 5 | (1) | 22 | 29 | |
| Comprehensive income (loss), net of tax, attributable to parent: | (1) | (1) | 6 | 5 | (1) | 22 | 29 | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.